Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tariq Gheith

Neurology East Lansing, MI Medical Doctor

NPI 1609213909 CMS profile 750631

804 Service Rd # A217, East Lansing, MI 48824

Open in the dashboard

General payments

$346,777

555 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tariq Gheith of East Lansing, MI is reported in the CMS Open Payments database as having received $346,777 across 555 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $129,607 176
2024 General $65,678 106
2023 General $90,845 148
2022 General $32,495 56
2021 General $18,684 50
2020 General $9,435 18
2019 General $33 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tariq Gheith
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Tariq Gheith were reported at $129,607. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Tariq Gheith Neurology median Middle half National median
2019 $33 $474 $118–$2,177 $163
2020 $9,435 $367 $82–$2,309 $114
2021 $18,684 $438 $104–$2,547 $132
2022 $32,495 $442 $103–$2,388 $149
2023 $90,845 $464 $119–$2,312 $160
2024 $65,678 $468 $119–$2,323 $164
2025 $129,607 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SK Life Science, Inc. $187,635 253 payments
  2. UCB, Inc. $133,900 215 payments
  3. LivaNova USA, Inc. $19,043 68 payments
  4. Pfizer Inc. $5,754 3 payments
  5. NeuroPace, Inc. $107 1 payment
  6. AbbVie, Inc. $100 5 payments
  7. Novartis Pharmaceuticals Corporation $83 4 payments
  8. Neurelis, Inc. $60 1 payment
  9. EMD Serono, Inc. $33 1 payment
  10. Amgen Inc. $33 2 payments
  11. Other $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $160,350 69 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $126,515 60 payments
  3. Travel and Lodging $38,047 234 payments
  4. Consulting Fee $12,095 7 payments
  5. Food and Beverage $9,769 185 payments
Products named General payments · program years 2019–2025
  1. XCOPRI $186,732 241 payments
  2. Briviact $66,469 99 payments
  3. Nayzilam $51,858 82 payments
  4. VNS THERAPY SENTIVA MODEL 1000 GENERATOR Neurology $12,899 31 payments
  5. NURTEC ODT $5,754 3 payments
  6. VNS THERAPY SENTIVA MODEL 1000 GENERATOR Cardiology/Vascular Diseases $5,677 26 payments
  7. Fintepla $4,863 12 payments
  8. VNS Therapy $351 2 payments
  9. VNS - Sentiva $116 9 payments
  10. RNS Neurostimulator Kit $107 1 payment
  11. Other $326 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,991

Median for Neurology: 833

Drug cost

$1,140,502

Median for Neurology: $202,670

Branded share of claims

43.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Briviact Brivaracetam Brand 358 $511,705
Xcopri Cenobamate Brand 323 $474,634
Aimovig Autoinjector Erenumab-Aooe Brand 44 $37,357
Nurtec Odt Rimegepant Sulfate Brand 35 $37,239
Nayzilam Midazolam Brand 52 $36,753
Lacosamide Generic 244 $16,750
Levetiracetam Generic 342 $10,485
Lamotrigine Generic 360 $4,350
Lamotrigine Er Lamotrigine Brand 14 $3,519
Carbamazepine Er Carbamazepine Brand 21 $2,864

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$183,826

Of which drugs: $151,398

Medicare patients

197

Average age 66

Services billed

30,897

97 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 41%
Diabetes 34%
Ischemic heart disease 28%
Depression 28%
Chronic kidney disease 26%
Heart failure 22%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 32 30,495 $151,399

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XCOPRI
  • SK Life Science, Inc. $27,180
$27,180 323 —
Briviact
  • UCB, Inc. $12,422
$12,422 358 —
Nayzilam
  • UCB, Inc. $11,370
$11,370 52 —
Fintepla
  • UCB, Inc. $4,728
$4,728 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

555 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record